Merck & Co. Inc. (NYSE:MRK) and Scynexis Inc said they are broadening the scope and extending the term of their multi-year research collaboration.

The collaboration was initiated last year to discover and develop novel anti-infective drugs.

Scynexis uses proprietary Medchem-Factory and Helos technologies to accelerate identification of novel drug compounds active against Merck’s screening targets.

Merck will receive exclusive worldwide rights to any products developed through the collaboration. Scynexis will receive milestone payments if products are developed. It will receive royalties on sales of any commercial products that result.

Scynexis is headquarted in the Research Triangle and has a European operation located near Cambridge, England.